1769 related articles for article (PubMed ID: 35924918)
1. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
[TBL] [Abstract][Full Text] [Related]
2. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
[TBL] [Abstract][Full Text] [Related]
3. Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.
Ishimaru H; Nishimura M; Shigematsu H; Marini MI; Hasegawa N; Takamiya R; Iwata S; Mori Y
J Virol; 2024 May; 98(5):e0041624. PubMed ID: 38624232
[TBL] [Abstract][Full Text] [Related]
4. 35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope.
Wang X; Chen X; Tan J; Yue S; Zhou R; Xu Y; Lin Y; Yang Y; Zhou Y; Deng K; Chen Z; Ye L; Zhu Y
Cell Host Microbe; 2022 Jun; 30(6):887-895.e4. PubMed ID: 35436443
[TBL] [Abstract][Full Text] [Related]
5. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
6. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
7. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
8. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL
J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572
[TBL] [Abstract][Full Text] [Related]
9. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
[TBL] [Abstract][Full Text] [Related]
10. The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2.
Xiong H; Sun H; Wang S; Yuan L; Liu L; Zhu Y; Zhang J; Huang Y; Qi R; Jiang Y; Ma J; Zhou M; Ma Y; Fu R; Yan S; Yue M; Wu Y; Wei M; Wang Y; Li T; Wang Y; Zheng Z; Yu H; Cheng T; Li S; Yuan Q; Zhang J; Guan Y; Zheng Q; Zhang T; Xia N
Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2204256119. PubMed ID: 35972965
[TBL] [Abstract][Full Text] [Related]
11. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants.
Ishimaru H; Nishimura M; Tjan LH; Sutandhio S; Marini MI; Effendi GB; Shigematsu H; Kato K; Hasegawa N; Aoki K; Kurahashi Y; Furukawa K; Shinohara M; Nakamura T; Arii J; Nagano T; Nakamura S; Sano S; Iwata S; Okamura S; Mori Y
J Virol; 2023 Jun; 97(6):e0028623. PubMed ID: 37191569
[TBL] [Abstract][Full Text] [Related]
12. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
[TBL] [Abstract][Full Text] [Related]
13. A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy.
Meng L; Zha J; Zhou B; Cao L; Jiang C; Zhu Y; Li T; Lu L; Zhang J; Yang H; Feng J; Gu Z; Tang H; Jiang L; Li D; Lavillette D; Zhang X
PLoS Pathog; 2023 Jan; 19(1):e1011085. PubMed ID: 36706160
[TBL] [Abstract][Full Text] [Related]
14. A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses.
Wang Y; Hao A; Ji P; Ma Y; Zhang Z; Chen J; Mao Q; Xiong X; Rehati P; Wang Y; Wang Y; Wen Y; Lu L; Chen Z; Zhao J; Wu F; Huang J; Sun L
Nat Commun; 2024 Jun; 15(1):5127. PubMed ID: 38879565
[TBL] [Abstract][Full Text] [Related]
15. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies.
Wang Y; Zhang X; Ma Y; Wang Y; Zhan W; Zheng Q; Zhang M; Ji P; Liu M; Liu Q; Sun T; Zhu T; Wen Y; Sun L; Zhao J; Wu F; Chen Z; Huang J
Cell Discov; 2022 Oct; 8(1):104. PubMed ID: 36207299
[TBL] [Abstract][Full Text] [Related]
16. A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD.
Wang X; Hu A; Chen X; Zhang Y; Yu F; Yue S; Li A; Zhang J; Pan Z; Yang Y; Lin Y; Gao L; Zhou J; Zhao J; Li F; Shi Y; Huang F; Yang X; Peng Y; Tu L; Zhang H; Zheng H; He J; Zhang H; Xu L; Huang Q; Zhu Y; Deng K; Ye L
Signal Transduct Target Ther; 2022 Apr; 7(1):114. PubMed ID: 35383141
[TBL] [Abstract][Full Text] [Related]
17. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
18. Cryo-EM structure of the SARS-CoV-2 Omicron spike.
Cerutti G; Guo Y; Liu L; Liu L; Zhang Z; Luo Y; Huang Y; Wang HH; Ho DD; Sheng Z; Shapiro L
Cell Rep; 2022 Mar; 38(9):110428. PubMed ID: 35172173
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.
Li CJ; Chao TL; Chang TY; Hsiao CC; Lu DC; Chiang YW; Lai GC; Tsai YM; Fang JT; Ieong S; Wang JT; Chang SY; Chang SC
Microbiol Spectr; 2022 Apr; 10(2):e0181421. PubMed ID: 35293796
[TBL] [Abstract][Full Text] [Related]
20. An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant.
Yuan M; Zhu Y; Liu G; Wang Y; Wang G; Zhang G; Ye L; Qian Z; Liu P
One Health Adv; 2023; 1(1):12. PubMed ID: 37521533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]